Terms: = Colorectal cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Clinical Outcome
5 results:
1. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Sunakawa Y; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Cancer; 2015 Jun; 121(11):1898-905. PubMed ID: 25690670
[TBL] [Abstract] [Full Text] [Related]
3. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Volz NB; Stintzing S; Zhang W; Yang D; Ning Y; Wakatsuki T; El-Khoueiry RE; Li JE; Kardosh A; Loupakis F; Cremolini C; Falcone A; Scherer SJ; Lenz HJ
Pharmacogenomics J; 2015 Feb; 15(1):69-76. PubMed ID: 25069475
[TBL] [Abstract] [Full Text] [Related]
4. pdgfrα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
Estevez-Garcia P; Castaño A; Martin AC; Lopez-Rios F; Iglesias J; Muñoz-Galván S; Lopez-Calderero I; Molina-Pinelo S; Pastor MD; Carnero A; Paz-Ares L; Garcia-Carbonero R
BMC Cancer; 2012 Nov; 12():514. PubMed ID: 23146028
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
[TBL] [Abstract] [Full Text] [Related]
